To examine the potential role of stem-cell factor (SCF) in cancer chemotherapy, we have administered it t o mice either before or after 5-fluorouracil (5-FU). When polyethylene glycolated (PEG-ylated) SCF was administered t o mice before 5-FU, it had a significant sensitizing effect on primitive bone marrow cells. Examination of the hematopoietic status of these mice showed that the damage caused by 5-FU t o both bone marrow and spleen hematopoiesis was exaggerated when it was preceded by SCF. SCF given before each of two 5-FU treatments at 7-day intervals resulted in the death of all treated mice. The time of death and hematopoietic status of these animals are compatible with the onset of hypoplastic marrow failure leading t o pancytopenia and death. SCF given after 5-FU had little impact either on the initial degree of hematopoietic damage or subsequent recovery. Gut populations were similarly sensitized t o 5-FU by prior treatment with SCF, and the damage caused t o intestinal populations was greater than that resulting from 5-FU alone. This indicates that the different tissues may be similarly sensitized by SCF. The sensitizing effect of SCF
To examine the potential role of stem-cell factor (SCF) in cancer chemotherapy, we have administered it t o mice either before or after 5-fluorouracil (5-FU). When polyethylene glycolated (PEG-ylated) SCF was administered t o mice before 5-FU, it had a significant sensitizing effect on primitive bone marrow cells. Examination of the hematopoietic status of these mice showed that the damage caused by 5-FU t o both bone marrow and spleen hematopoiesis was exaggerated when it was preceded by SCF. SCF given before each of two 5-FU treatments at 7-day intervals resulted in the death of all treated mice. The time of death and hematopoietic status of these animals are compatible with the onset of hypoplastic marrow failure leading t o pancytopenia and death. SCF given after 5-FU had little impact either on the initial degree of hematopoietic damage or subsequent recovery. Gut populations were similarly sensitized t o 5-FU by prior treatment with SCF, and the damage caused t o intestinal populations was greater than that resulting from 5-FU alone. This indicates that the different tissues may be similarly sensitized by SCF. The sensitizing effect of SCF TEM-CELL FACTOR (SCF),' also known as kit ligand (m)' or mast-cell growth factor (MGF)? is a molecule that has a role to play in systems as diverse as hematopoiesis: primordial germ cells,5" melanocytes,7 and perhaps some forms of With regard to the hematopoietic system, SCF has been shown to have a modest direct effect on survival, proliferation, and development of some hematopoietic progenitor-cell populations, but is also a potent synergistic factor, interacting with a range of more lineage-restricted growth factors, and including among its target cells some of the most primitive clonogenic hematopoietic cells detectable in vitro. ' In vivo, when applied as a single agent, SCF is a relatively modest stimulator of neutrophil number,".'2 while significant effects on other mature cell lineages (with the notable exception of mast cells".14) have been difficult to demonstrate. The most marked ability of SCF, and one that was not predicted from its activities in vitro, is the ability to mobilize considerable numbers of primitive hematopoietic cells to the peripheral blood, particularly when used in combination with granulocyte colony-stimulating factor (G-CSF)."3'5 Recent data have indicated that SCF can offer a significant degree of protection against death caused by high-dose gamma-irradiation, 16 an effect not dissimilar to that of interleukin-l (IL-l)," and one possibly mediated via alterations in the cycling status of primitive hematopoietic stem cells. However, in contrast to other hematopoietic growth factors that have been shown to accelerate recovery of hematopoietic cells following cytoreductive therapy, the therapeutic potential of SCF remains largely unexplored. To examine this further and also to better define the target cells of SCF in vivo, we have now investigated the effects of treatment with SCF both before and after treatment with 5-fluorouracil (5-FU), a widely used cell cycledependent cytotoxin. Furthermore, since transforming growth factor (TGF)-P has been shown to reverse some of the effects of SCF in vitro," and has also been shown by us S was reversed by concurrent administration of transforming growth factor (TGF)-p3, and survival of the majority of the mice was ensured. Examination of hematopoiesis in mice treated concurrently with SCF and TGF-P3 showed that the degree of marrow and spleen damage had reverted t o that caused by 5-FU alone. In further experiments, 10046 survival and normal hematopoiesis could be attained by transplantation of 1 million syngeneic bone marrow cells 24 hours after 5-FU treatment following SCF sensitization. These data indicate that PEG-ylated SCF can sensitize normally resistant hematopoietic and gut stem cells t o the effects of 5-FU. This sensitization resulted in effective eradication of hematopoiesis in SCF-pretreated/5-FU-treated animals and their subsequent death from marrow failure. These findings imply that SCF pretreatment may represent a novel method of increasing the effectiveness of conventional chemotherapy, making marrow ablation more effective without drug dose escalation and perhaps sensitizing some tumor cells to the effects of therapy. to suppress cycling of bone marrow progenitors that are regenerating following cytotoxic insult," we have also examined the effects of TGF-P when injected concurrently with SCF.
MATERIALS AND METHODS

Mice
Mice were female B6D2F1 of 8 to 10 weeks of age at the beginning of the experiments. All were maintained with food and water ad libitum for the duration of the studies. Typically, experimental groups consisted of between 10 and 30 weight-matched (20 to 22 g) animals. Mice were observed daily, and any animals appearing moribund were humanely destroyed.
In Vitro Progenitor Cells
Hematopoietic progenitor cells were assayed in semisolid agar cultures in the presence of IL-3. Briefly, I mL of cell suspensions prepared in lscoves medium and containing S X 10' bone marrow cells or S X 10' spleen cells was supplemented with 20% preselected horse serum, 10% BSA, S I murine IL-3-conditioned medium. and 0.33% Agar Noble (Difco, East Molesey, UK), and aliquoted into triplicated 35-mm Falcon petri dishes (Becton-Dickinson, Oxford, UK). These were left at 37°C in fully humidified S I COz and 5% O2 in nitrogen for I I days, after which they were scored under an Olympus SZ microscope. Colonies of greater than S0 cells were scored and numbers of colony-forming cells calculated per donor femur or spleen. Details of the assay are given by Heyworth and Spooncer."
Gut and Skin Studies
Preliminary studies of the gut and skin from animals in groups treated with two cycles of S-FU were made to establish the degree of damage suffered in these tissues.
Fixation. embedding. and staining. The complete small intestine was removed from each animal, fixed overnight at 4°C in 10% formal saline in PBS. and then washed in 70% ethanol for 24 hours. From each small intestine. five 4-cm segments were removed corresponding to regions from the duodenum, jejunum, proximal, middle, and distal ileum. These segments were then formed into bundles," dehydrated, and embedded in Paraplast wax. TS sections of 4 pm were cut and stained with hematoxylin and eosin, periodic acid-Schiff/ Alcian blue to reveal goblet cells, and biotinylated Pokeweed lectin and avidin peroxidase to reveal Paneth cells.
A 2-X l-cm strip of dorsal skin was also taken from each animal and fixed as above. The skin was then embedded on end and 4-pm TS sections cut. These sections were stained with hematoxylin and eosin.
Morphologic measurements and kinetic indices. All of the morphologic measurements were made with a microscope using a calibrated eyepiece micrometer at 30, 12.5.200. or S00 x magnification.
For every parameter, at least 30 measurements in the five segments of small intestine from each animal were taken; there were three animals per treatment group. 
Statistics
Survival analysis was performed using a log-rank test in BMDP statistical software (Berkeley, CA) running on an IBM PC. Differences between weights and hematopoietic progenitor population sizes were analyzed using Student's t test of Stat-Sak statistical software running on an IBM PC.
RESULTS
Survival
All mice injected with camer alone, SCF alone, or TGFp alone survived the three cycles of treatment (Fig 2) . How- (6) plus S-FU combination. followed by intravenous infusion of 10" isologous bone marrow cells 24 hours after the injection of S-FU. All of these combinations were repeated on a 7-day cycle (Fig l) .
Assessment of Hematopoiesis
Blood (20 pL) was withdrawn from the lateral tail vein and analysis of peripheral blood parameters was made with a Sysmex F-800 blood analyxr (Tao Medical, Milton Keynes, UK). From a further small sample, blood films were prepared, stained with Tetrachrome, and differential counts made. Mice were not repeatedly sampled. After blood sampling mice were humanely killed, femora and spleen were removed and single cell suspensions prepared for clonogenic assays.
Colony-Forming Units-Spleen
Colony-forming units-spleen (CFU-S) were assessed by intravenous injection of appropriate dilutions of the cell suspensions into mice that had been potentially lethally irradiated (IS Gy, "CO gamma-rays, 0.94 Gyh). Details of the method are given by Lord.'" Groups of 10 mice were injected, and all experiments had irradiationonly control groups, which showed eradication of endogenous colony growth in all experiments; all mice were killed I I days after injection.
For personal use only. on October 22, 2017. by guest www.bloodjournal.org From ever, 5-FU at 125 mg/kg was somewhat toxic and reduced survival to 80% of the control group after only two cycles of treatment (Fig 2) . When TGF-P was introduced in the treatment protocol before the 5-FU injection, the survival of the animals was improved (to 95% of control), although this was not significant (P = .lo). However, if SCF was administered before treatment with 5-FU, no mice (of 50 treated) survived to the third cycle of treatment and, in these animals, death usually occurred between days 14 and 20 (Fig  2) . The survival of these animals was significantly different from those given 5-FU alone (P = ,0001). In other words, TGF-P had a modest protective effect on survival of animals if injected before treatment with 5-FU, while SCF had a significant sensitizing effect. However, of particular interest is that this sensitizing effect of SCF could be abrogated by concomitant treatment with TGF-P (Fig 2) (P = ,003). Indeed, the survival of these animals was not significantly different from that of those treated with 5-FU alone ( P = .6). However, if mice received SCF after treatment with 5-FU, then approximately 60% survived and, although prior treatment with TGF-0 improved the survival rates to 85%, these figures were not significantly different either from each other or from mice treated with 5-FU alone ( P = .82 and .82, respectively) (Fig 2) . The precise cause of death of animals in these various groups was not ascertained; however, examination of several mice that were close to death showed very pale foot color, loss of coat condition, and weight loss.
Effect on Peripheral Blood
Each of the agents in the control series of experiments (ie, carrier fluid, SCF alone, TGF-P alone) had little or no effect on blood leukocyte count, red blood cell count, or platelet 3493 count when measured on day 4 of the cycle of therapy (Fig  1) . Injection of 5-FU reduced leukocyte counts after a single treatment, although the second cycle of 5-FU caused more severe damage (Fig 3) . Inclusion of TGF-0 before each cycle of 5-FU did not offer significant protection to leukocytes and numbers fell to levels similar to those in animals treated with 5-FU alone. When SCF was administered before 5-FU, leukocyte numbers were reduced to 45% ? 12% of control after one cycle and to 16% ? 4% after two cycles, numbers that differ significantly from control numbers, but not from numbers in mice treated with 5-FU alone. When SCF was given after 5-W, numbers were slightly, although not significantly, worse than in those given 5-FU alone.
The pattern of reduction in platelets followed broadly the pattern in leukocytes. Where SCF preceded 5-FU, thrombocytopenia was most pronounced (<400 X 106/mL blood; control, 921 ? 57) and TGF-P was unable to reverse the depression. Erythrocytes were also reduced (from control of 983 +-13 to 655 X 109/mL), the most marked effect being with SCF(b) plus 5-FU.
Effect on Hematopoietic Progenitors
Measurements were made 3 days after 5-FU during each of two cycles of treatment. Mice treated with SCF before 5-FU showed the most severe depletion in bone marrow CFU-S numbers. The second cycle reduced numbers to the limit of detection of the assay. CFU-S numbers in all other treatment groups were higher than this, including 5-FU alone, which reduced marrow CFU-S to 23.9% 2 3.3% of control after one cycle and 7% f 0.8% after two cycles (Fig 4) .
Assessment of in vitro IL-3-responsive progenitor cells For in the bone marrow of mice in the various groups reflected a similar pattern of damage, with the reduction in numbers per femur being most marked in SCF(b) plus 5-FU at 1.1 % 2 0.12% of control after one cycle and 0.3% 2 0.08% after two cycles (Fig 5) .
The effect of the treatment protocols on splenic hematopoiesis is obscured somewhat by the (previously documented) ability of SCF to stimulate hematopoietic activity in For personal use only. on October 22, 2017. by guest www.bloodjournal.org From Spleen IL-3-responsive colony-forming cells in various treatment groups (see Fig 1) after cycle 1 and 2 of treatment. Four independent experiments were performed in total; data are means 2 SD. Where numbers differ significantly from control, it is indicated 'P < .05 and **P = .01, and where it differs in 5-FU-treated groups from 5-FU treatment alone, it is indicated 'P < . 05 and "*P = .01. ie, G-CSF was unable to abrogate the sensitizing effect of the SCF, but this effect was again partially reversed by concurrent administration of TGF-P. Having established that survival and gross hematopoiesis were severely damaged by pretreatment with SCF before 5-FU, we attempted to address more specifically the cause of death in these animals, and performed marrow transplantation 24 hours after 5-FU. Figure 9 shows that transplantation of lo6 bone marrow cells rescued mice that otherwise would be expected to die from two cycles of SCF(b) plus 5-FU.
All hematopoietic parameters were improved in these mice.
The most marked increases were in bone marrow and spleen progenitor populations, although peripheral blood numbers were also significantly improved (data not shown).
Gut and Skin Studies
The most marked changes occurred in the villus height and mean (crypt) mitotic index. These data showed significant reductions only in the SCF(b) plus 5-FU mice, while mice that received SCF(b) plus 5-FU and marrow transplant showed a degree of hyperproliferation. Overall, changes in the epidermis or dermis of these four groups of mice were not so significant. Due to the low mitotic activity of this tissue, changes in the proliferative activity of the epidermis could not be accurately determined. All gut and skin results are summarized in Table 1 .
DISCUSSION
The initial aim of these studies was to determine if SCF could ameliorate the hematotoxicity of 5-FU, a drug that is often used in treatment protocols for malignant disease. However, the premature death of animals in which SCF preceded 5-FU was unexpected, and when death occurred it was between 16 and 19 days from the commencement of 5-FU treatment, ie, 9 to 12 days after the second injection of 5-FU, a time-scale compatible with hematopoietic death. For this reason, further investigations focused on the scheduling of SCF treatment, and it was found that the hematotoxicity of SCF was much more profound when given before 5-FU than when given after. In the latter case, SCF did little to improve recovery or to exaggerate the non-life-threatening damage caused by the 5-FU alone, whereas the second cycle of SCF administered before 5-FU effectively eradicated hematopoiesis in treated animals. Examination of the blood and marrow of these animals when close to death showed pancytopenia and hypoplastic marrow failure. The reason for this bone marrow failure and subsequent death was not immediately apparent.
5-FU is widely accepted as a cell cycle-specific cytotoxin and, for this reason, has been used experimentally to eradicate the proliferating hematopoietic progenitor cells and increase the relative concentration of stem cells by virtue of their relatively quiescent state. Lerner and Harrison,23 for example, have shown that between 5 and 8 days after administration of 5-FU, cells capable of long-term reconstitution are at their highest concentration in the marrow of treated mice. Furthermore, the functional integrity of these cells is clearly maintained, since repeated cycles of 5-FU are followed by hematopoietic regeneration with little or no mortality. In contrast, our data show that when SCF precedes even a single cycle of 5FU, there is a dramatic reduction in the multipotential CFU-S population and that the second cycle (timed to coincide with the maximum concentration of longterm reconstituting cells [putative totipotent stem cells] in the bone marrow and presumably an elevated proliferative status in these cells), if again preceded by SCF, effectively eradicated hematopoiesis totally. Thus, the cause of marrow failure in these mice probably results from a combination of the second application of 5-FU being timed to maximize damage to the most primitive cells and sensitization of these cells, by SCF, to the toxic effects of 5-FU. Since 5-FU is preferentially toxic to proliferating cells, a natural conclusion to draw from our experiments is that SCF has recruited more of the stem cells to the cell cycle and that the killing of these cells by 5-FU has resulted in marrow failure, pancytopenia,
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. For affects proliferating cells generally, rather than only those in the S-phase of the cell cycle. Nonetheless, the effective eradication of hematopoiesis by pretreatment with SCF followed by 5-FU, and its reversal by transplantation of hematopoietic cells, suggests that this novel combination of cytokine plus cytotoxic agent could have therapeutic potential for bone marrow ablation. Furthermore, it is possible that recruitment may occur of cell populations that are refractory to cytotoxins, such as acute myeloid leukemia (where relapse remains a problem), small-cell lung cancer, and breast carcinoma, in which both SCF and/or its receptor (encoded by c-kit) have been identified on the malignant cells.'0,26
Having determined that SCF can sensitize putative hematopoietic stem cells to the toxic effects of 5-FU, we then investigated whether the effects of SCF could be prevented by cotreatment with TGF-P. This was particularly interesting in view of our own" and other dataz7 showing that TGF-P can inhibit the proliferation of hematopoietic cells. However, the regimen of TGF-P administration used here is different in several respects from our previous studies. First, we have used TGF-P3-a different isoform of the molecule-which we have shown to be at least as potent as TGF-P1 both in in vitro and in vivo assay systems (unpublished data). Second, we have used a different acute schedule of TGF-P to minimize effects such as weight loss, cachexia, and, in extreme cases, death. In place of our 5-day, 100-pg/kg/d treatment with TGF-PI, we have used five injections of 2 pg per injection (-80 pgkg) repeated five times in 24 hours (total dose, -500 pg/kg/d).
However, even with this protocol, weight loss remained significant in TGF-P-treated mice. Nonetheless, the improved survival seen when mice pretreated with SCF followed by 5-FU were also given TGF-P3 indicates that a useful marrow-sparing effect with acceptable side effects can be obtained with TGF-P3 (indicating the possible clinical usefulness of TGF-P3 in a short-tennhigh-dose strategy). The inclusion of TGF-P3 in the most damaging SCF pretreatment followed by 5-FU combination had a clear protective effect on hematopoiesis in both the marrow and the spleen, and effectively prevented the marrow damage from progressing to a seriously life-threatening level in approximately half the mice otherwise destined to die.
Similar to the hematopoietic system, sensitivity of the gut mucosa to damage limits cytotoxic and radiotherapeutic cancer regimens. Consequently, conditions that modify damage of therapeutic regimes to normal gut epithelium are of clinical interest. Single doses of an agent like 5-FU are moderately efficient at sterilizing the proliferative epithelial crypt population in the mouse small intestine." The preliminary results presented here suggest that pretreatment with SCF significantly increased the deleterious effects of 5-FU on the mucosa compared with 5-FU alone (Table l) . In the animals For personal use only. on October 22, 2017. by guest www.bloodjournal.org From treated with SCF(b) plus 5-FU, the intestinal epithelium was hypoproliferative, with low mitotic activity and villus atrophy. Additional indications of damage were the presence of cellular debris and altered mucin secretion into the lumen of these guts. However, the deleterious effects of SCF pretreatment were blocked by concurrent treatment with TGFp3, a finding that extends our previous data on the cytostatic effects of TGF-p1 on mucosal proliferation." The substantial proliferation, as indicated by the elevated crypt mitotic index (Table l) , in mice that received marrow transplantation in addition to the 5-FU and SCF pretreatment indicates a marked degree of recovery in this tissue. The reason for the mitotic index returning to approximately normal levels is not immediately apparent, but may be an effect of increased feeding activity associated with a more general improvement in health.
What is the mechanism underlying the sensitization of cells by SCF? How is TGF-p exerting its protective effects? We can only speculate at present, but the ability to sensitize hematopoietic stem cells is not a feature held in common with G-CSF, and recent data (F. Ruscetti, personal communication, June 1993) indicate that TGF-p may downregulate the activity of SCF receptors on certain cells, perhaps beginning to indicate a mechanism for some of the inhibitory effects of TGF-p.
Overall, we conclude that SCF is capable of sensitizing primitive hematopoietic stem cells to the effects of 5-FU and that this effect is opposed by TGF-p3. Hematopoietic ablation may be more thorough after this type of combination therapy, offering the possibility of more effective eradication of endogenous hematopoiesis in transplant situations, but also indicating caution where this combination may be considered when hematopoietic ablation is not the primary intention. For personal use only. on October 22, 2017. by guest www.bloodjournal.org From
